Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02382614 · ClinicalTrials.gov registry record · NA

Spiration Valves Against Standard Therapy

A NA study, sponsored by Olympus Corporation of the Americas.

Terminated
Registry status
NA
Development phase
75
Enrollment target

NCT02382614 is a NA study that was terminated before completion, run by Olympus Corporation of the Americas. The registered enrollment target is 75 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02382614, a NA study, was terminated before completion, sponsored by Olympus Corporation of the Americas.

TERMINATED
Registry status
NA
Development phase
75 participants
Enrollment target

Study Summary

VAST is a multicenter, prospective, randomized, controlled study designed to evaluate treatment of persistent air leak with the SVS as compared to standard chest tube drainage management and other standard-of-care interventions in the control group. Eligible subjects will be randomized to receive either Spiration Valves (investigational arm) or continue standard-of-care treatment (control arm). Once the air leak has resolved, Spiration Valves should be removed.

Interventions

  • DEVICE Spiration Valve System

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2015-05
Est. Completion 2022-02
Phase NA

What the Registry Record Tells You About NCT02382614

The ClinicalTrials.gov registry entry for NCT02382614 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Olympus Corporation of the Americas, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Spiration Valve System is the first listed.

NCT02382614 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02382614 about?

NCT02382614 is a clinical study titled "Spiration Valves Against Standard Therapy". VAST is a multicenter, prospective, randomized, controlled study designed to evaluate treatment of persistent air leak with the SVS as compared to standard chest tube drainage management and other standard-of-care interventions in the control group. Eligible subjects will be randomized to receive ei...

What is the current status of trial NCT02382614?

This trial is currently terminated. It is a NA study. The enrollment target is 75 participants. The study started on 2015-05. Estimated completion is 2022-02.

What interventions are being tested in trial NCT02382614?

The interventions under investigation include: Spiration Valve System (DEVICE).

Who is sponsoring clinical trial NCT02382614?

This trial is sponsored by Olympus Corporation of the Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.